SCHEMBL4815213

SCHEMBL4815213

[CH]=CCc1ccc2ncccc2c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.52
RAB9A P51151 3/20 0.52
POLB P06746 2/20 0.52
ALDH1A1 P00352 3/20 0.49
MAPT P10636 3/20 0.49
ATM Q13315 2/20 0.49
KDM4E B2RXH2 1/20 0.49
TP53 P04637 1/20 0.49
HSP90AA1 P07900 1/20 0.49
HSP90AB1 P08238 1/20 0.49
TSHR P16473 1/20 0.49
CASP1 P29466 1/20 0.49
HTT P42858 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
HSD17B10 Q99714 1/20 0.49
MET P08581 5/20 0.46
DAO P14920 1/20 0.46
CHKA P35790 1/20 0.45
MEN1 O00255 1/20 0.44
CASP3 P42574 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL359532 0.84 NPC1 (0.53) NPC1RAB9APOLBALDH1A1MAPT
SCHEMBL9277814 0.83 NPC1 (0.52) NPC1RAB9APOLBALDH1A1MAPT
SCHEMBL28879869 0.83 NPC1 (0.52) NPC1RAB9APOLBALDH1A1MAPT
SCHEMBL4375850 0.80 NPC1 (0.57) NPC1RAB9APOLBALDH1A1MAPT
SCHEMBL30586439 0.80 ALDH1A1 (0.58) NPC1RAB9APOLBALDH1A1MAPT
SCHEMBL29673226 0.80 ALDH1A1 (0.58) NPC1RAB9APOLBALDH1A1MAPT
SCHEMBL507149 0.80 ALDH1A1 (0.58) NPC1RAB9APOLBALDH1A1MAPT
SCHEMBL27594293 0.80 NPC1 (0.49) NPC1RAB9APOLBALDH1A1MAPT
Iodide SCHEMBL20524052 0.79 ALDH1A1 (0.56) NPC1RAB9APOLBALDH1A1MAPT
SCHEMBL4815350 0.77 PDGFRB (0.50) RAB9AALDH1A1KDM4ESMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7365174-B2 Azalide and azalactam derivatives and method for producing the same MEIJI SEIKA KAISHA, LTD. (JP) 2008-04-29 US claimed
US-20070042974-A1 Nozel azalide and azalactam derivatives and method for producing the same MEIJI SEIKA KAISHA, LTD. (JP) 2007-02-22 US claimed
EP-1661904-A1 NOVEL AZALIDE AND AZALACTAM DERIVATIVES AND PROCESS FOR THE PRODUCTION OF THE SAME MEIJI SEIKA KAISHA LTD. (JP) 2006-05-31 EP claimed
US-7365174-B2 Azalide and azalactam derivatives and method for producing the same MEIJI SEIKA KAISHA, LTD. (JP) 2008-04-29 US disclosed
US-20070042974-A1 Nozel azalide and azalactam derivatives and method for producing the same MEIJI SEIKA KAISHA, LTD. (JP) 2007-02-22 US disclosed
EP-1661904-A1 NOVEL AZALIDE AND AZALACTAM DERIVATIVES AND PROCESS FOR THE PRODUCTION OF THE SAME MEIJI SEIKA KAISHA LTD. (JP) 2006-05-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070042974-A1 Nozel azalide and azalactam derivatives and method for producing the same BCL6, NR4A1, NR4A2 NPC1 923/4885RAB9A 2161/4885POLB 3203/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.